pillbase.ru

Rinvoq

Active substance: upadacitinib

upadacitinib

Centralised EU authorisationActive

Marketing holder: AbbVie Deutschland GmbH & Co. KG

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • Rinvoq
    TABLET, EXTENDED RELEASE · UPADACITINIB 30 mg/1
    0074-2310
    AbbVie Inc.
  • Rinvoq
    TABLET, EXTENDED RELEASE · UPADACITINIB 15 mg/1
    0074-2306
    AbbVie Inc.
  • Rinvoq
    TABLET, EXTENDED RELEASE · UPADACITINIB 45 mg/1
    0074-1043
    AbbVie Inc.
  • Rinvoq
    SOLUTION · UPADACITINIB 1 mg/mL
    0074-2320
    AbbVie Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-4643-7d9f-aa20-c5c1335311f6,01a1208d-f9f9-745c-8b99-dec3645de431,01a12093-3d9e-7d6a-a7e2-ecda25099ed2,01a1209c-c983-791b-9f6e-5d4259ea9f4c;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004760
Registration status
Active
ATC code
L04AA44
Sources
  • product · EMA · EMEA/H/C/004760 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004760 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004760 · Verified 2026-10-09